HC Wainwright Expects Increased Earnings for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2025 EPS estimates for Nuvectis Pharma in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.28) for the quarter, up from their previous forecast of ($0.31). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma's Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($1.40) EPS, FY2027 earnings at ($1.60) EPS and FY2028 earnings at ($1.90) EPS.

Other research analysts have also recently issued reports about the company. Laidlaw initiated coverage on Nuvectis Pharma in a research report on Monday, March 17th. They set a "buy" rating and a $19.00 price objective for the company. Maxim Group began coverage on shares of Nuvectis Pharma in a research note on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price target on the stock.

Nuvectis Pharma Stock Performance

Shares of NASDAQ NVCT traded up $0.61 during trading on Friday, reaching $9.04. The stock had a trading volume of 86,179 shares, compared to its average volume of 127,026. The company has a market cap of $213.66 million, a P/E ratio of -7.79 and a beta of -0.11. The business's 50-day moving average price is $9.03 and its 200-day moving average price is $7.20. Nuvectis Pharma has a fifty-two week low of $4.44 and a fifty-two week high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03.

Insider Activity

In other news, major shareholder Marlio Charles Mosseri purchased 12,444 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was acquired at an average price of $8.59 per share, with a total value of $106,893.96. Following the purchase, the insider now owns 2,896,565 shares in the company, valued at $24,881,493.35. This represents a 0.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have bought 36,261 shares of company stock worth $301,481. 35.78% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds have recently made changes to their positions in the business. Austin Wealth Management LLC acquired a new position in shares of Nuvectis Pharma during the 1st quarter worth about $393,000. Iridian Asset Management LLC CT bought a new position in shares of Nuvectis Pharma in the 1st quarter valued at $2,481,000. Oppenheimer & Co. Inc. lifted its holdings in Nuvectis Pharma by 64.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 41,000 shares of the company's stock worth $401,000 after buying an additional 16,000 shares during the period. Baldwin Wealth Partners LLC MA grew its stake in Nuvectis Pharma by 0.7% during the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock worth $3,502,000 after purchasing an additional 2,500 shares during the period. Finally, Blue Zone Wealth Advisors LLC bought a new stake in Nuvectis Pharma in the first quarter valued at $102,000. Institutional investors and hedge funds own 96.77% of the company's stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.